ZNTL · NASDAQ
Zentalis Pharmaceuticals (ZNTL) Stock Price & Fundamentals
Zentalis Pharmaceuticals (ZNTL) closed at $300.81 on Oct 9, 2026, down 0.74% from the previous close of $303.04.
Share price, past year
1Y +29.43%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $300.81 |
| Sep 30, 2026 | $303.78 |
| Aug 31, 2026 | $311.79 |
| Jul 31, 2026 | $317.26 |
| Jun 30, 2026 | $302.43 |
| May 29, 2026 | $329.17 |
| Apr 30, 2026 | $297.80 |
| Mar 31, 2026 | $272.90 |
| Feb 27, 2026 | $259.43 |
| Jan 30, 2026 | $255.91 |
| Dec 31, 2025 | $244.01 |
| Nov 28, 2025 | $233.30 |
| Oct 31, 2025 | $229.73 |
Key statistics
- Market cap
- $21.56B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.96
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$139.55M
- Shares outstanding
- 71.7M
- Dividend yield
- —
- 52-week range
- $228.16 – $331.43
Zentalis Pharmaceuticals's market cap is $21.56B, based on a share price of $300.81 and 71.7M shares outstanding as of Jun 30, 2026.
Financials
Zentalis Pharmaceuticals reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Zentalis Pharmaceuticals reported a net loss of $137.06M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | −100.0% | −$137.06M | — | −$1.91 | −$125.25M |
| FY2024ended Dec 31, 2024 | $67.43M | — | −$165.84M | −246.0% | −$2.33 | −$171.08M |
| FY2023ended Dec 31, 2023 | $0.00 | — | −$292.19M | — | −$4.47 | −$208.41M |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$236.81M | — | −$4.48 | −$166.30M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$35.22M | −$0.50 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$26.69M | −$0.37 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$26.87M | −$0.37 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$48.28M | −$0.67 |
| Q4 FY2024ended Dec 31, 2024 | $26.87M | −$47.47M | −$0.67 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$40.16M | −$0.56 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
| Q1 FY2024ended Mar 31, 2024 | $40.56M | — | — |
Company profile
- Name
- Zentalis Pharmaceuticals, Inc.
- Ticker
- ZNTL
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 10275 Science Center Drive, Suite 200, San Diego, CA 92121
- Fiscal year ends
- December
- SEC CIK
- 0001725160
Recent SEC filings
- Aug 14, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 18, 2026
- May 27, 2026
- May 21, 2026
- May 12, 2026
- May 12, 2026
Frequently asked questions
What is Zentalis Pharmaceuticals's stock price?
Zentalis Pharmaceuticals (ZNTL) closed at $300.81 on Oct 9, 2026, down 0.74% from the previous close of $303.04.
What is Zentalis Pharmaceuticals's market cap?
Zentalis Pharmaceuticals's market cap is $21.56B, based on a share price of $300.81 and 71.7M shares outstanding as of Jun 30, 2026.
How much revenue does Zentalis Pharmaceuticals make?
Zentalis Pharmaceuticals reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Does Zentalis Pharmaceuticals pay a dividend?
Zentalis Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Zentalis Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures